Literature DB >> 26417403

Genetic variants in hypothalamic-pituitary-adrenal axis genes and breast cancer risk in Caucasians and African Americans.

Hongmei Nan1, Joanne F Dorgan2, Timothy R Rebbeck3.   

Abstract

Elevated circulating levels of the adrenal androgen dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) are associated with increased breast cancer risk in prospective studies. Genetic variants in hypothalamic-pituitary-adrenal (HPA) axis genes may contribute to these circulating hormone levels, and consequently to breast cancer risk. No previous studies have examined the effects of genetic variants in HPA axis genes on breast cancer risk. We evaluated the associations of 49 single nucleotide polymorphisms (SNPs) in five HPA axis genes (NR3C1, NR3C2, CRH, CRHR1, and CRHBP) with the risk of breast cancer in the Women's Insights and Shared Experiences (WISE) Study of Caucasians (346 cases and 442 controls), as well as African Americans (149 cases and 246 controls). Of the 49 SNPs evaluated, one showed a nominal significant association (P for trend < 0.05) with breast cancer risk among Caucasians, and another two among African Americans. The age-adjusted additive odds ratio (OR) (95% confidence interval (95% CI)) of the SNP rs11747190[A] in the CRHBP gene for the risk of breast cancer among Caucasian women was 1.45 (1.09-1.94). The age-adjusted additive ORs (95% CIs) of two SNPs (CRHBP rs1700688[T] and CRHR1 rs17689471[C]) for the risk of breast cancer among African American women were 1.84 (1.13-2.98) and 2.48 (1.20-5.13), respectively. However, these SNPs did not show significant associations after correction for multiple testing. Our findings do not provide strong supportive evidence for the contribution of genetic variants in these HPA axis genes to the risk of developing breast cancer in either Caucasians or African Americans.

Entities:  

Keywords:  HPA axis genes; Single nucleotide polymorphism; breast cancer

Year:  2015        PMID: 26417403      PMCID: PMC4572091     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  28 in total

1.  Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.

Authors:  J F Dorgan; F Z Stanczyk; C Longcope; H E Stephenson; L Chang; R Miller; C Franz; R T Falk; L Kahle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-03       Impact factor: 4.254

2.  Re: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

Authors:  J F Dorgan; C Longcope; F Z Stanczyk; H E Stephenson; R N Hoover
Journal:  J Natl Cancer Inst       Date:  1999-02-17       Impact factor: 13.506

3.  Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.

Authors:  Timothy R Rebbeck; Andrea B Troxel; Amy H Walker; Saarene Panossian; Stephen Gallagher; Ekaterina G Shatalova; Rebecca Blanchard; Sandra Norman; Greta Bunin; Angela DeMichele; Michelle Berlin; Rita Schinnar; Jesse A Berlin; Brian L Strom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

4.  A polymorphism in the regulatory region of the corticotropin-releasing hormone gene in relation to cortisol secretion, obesity, and gene-gene interaction.

Authors:  R Rosmond; M Chagnon; C Bouchard; P Björntorp
Journal:  Metabolism       Date:  2001-09       Impact factor: 8.694

5.  Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.

Authors:  Timothy R Rebbeck; Andrea B Troxel; Yiting Wang; Amy H Walker; Saarene Panossian; Stephen Gallagher; Ekaterina G Shatalova; Rebecca Blanchard; Greta Bunin; Angela DeMichele; Stephen C Rubin; Mona Baumgarten; Michelle Berlin; Rita Schinnar; Jesse A Berlin; Brian L Strom
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

6.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.

Authors:  T Key; P Appleby; I Barnes; G Reeves
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

7.  Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Authors:  Stacey A Missmer; A Heather Eliassen; Robert L Barbieri; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

8.  Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men.

Authors:  Elisabeth F C van Rossum; Richard A Feelders; Annewieke W van den Beld; André G Uitterlinden; Joop A M J L Janssen; Wietske Ester; Albert O Brinkmann; Diederick E Grobbee; Frank H de Jong; Huibert A P Pols; Jan W Koper; Steven W J Lamberts
Journal:  Am J Med       Date:  2004-08-01       Impact factor: 4.965

9.  Common genetic origins for EEG, alcoholism and anxiety: the role of CRH-BP.

Authors:  Mary-Anne Enoch; Pei-Hong Shen; Francesca Ducci; Qiaoping Yuan; Jixia Liu; Kenneth V White; Bernard Albaugh; Colin A Hodgkinson; David Goldman
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

10.  Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study.

Authors:  A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  2 in total

1.  Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma.

Authors:  Hai-Bing Xia; Hui-Ju Wang; Luo-Qin Fu; Shi-Bing Wang; Li Li; Guo-Qing Ru; Xiang-Lei He; Xiang-Min Tong; Xiao-Zhou Mou; Dong-Sheng Huang
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

Review 2.  Stress sensing within the breast tumor microenvironment: how glucocorticoid receptors live in the moment.

Authors:  Carlos Perez Kerkvliet; Thu H Truong; Julie Hanson Ostrander; Carol A Lange
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.